Search

everythinglearnresearchcommunity

for

Search:↓

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The focus is on setting realistic expectations for these treatments.

A user is concerned about hair loss and acne from a one-week course of 70 mg/day oral prednisolone for severe tinnitus. They are asking if these side effects are common.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

Creatine may increase DHT levels, potentially causing hair loss in some people, though experiences vary. Treatments like finasteride or minoxidil are suggested to manage potential hair loss.

User suggests rotating scalp 180 degrees to address hair loss. Others discuss sanity, ethics, and similar procedures like scalp reduction and hair transplants.

Diffuse hair thinning and treatments like finasteride and minoxidil. Early detection and treatment are crucial for effective management.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The user is experiencing hair loss despite using finasteride and Rogaine, with conflicting diagnoses from different hospitals. One suggests no hair loss, while another recommends continuing medication; a suggestion to see a dermatologist for proper assessment is given.

An 18-year-old is experiencing worsening hair loss, feeling isolated, and considering treatments like Minoxidil and finasteride. Others suggest seeing a dermatologist to determine the cause and potential treatments.

A 20-year-old is experiencing hair thinning despite using minoxidil inconsistently for 1.5 years and is considering adding finasteride due to concerns about side effects. They are unsure whether to increase minoxidil application, start finasteride, or if the hair loss is exaggerated in their perception.

The user is experiencing significant hair loss and has tried treatments like PRP therapy, topical and oral Minoxidil, Finasteride, and dietary changes, with limited success. They are concerned about losing more hair before a scheduled hair transplant and are advised to postpone the transplant to allow medications more time to work.

The conversation expresses frustration over the lack of progress in hair loss treatments, with specific mentions of Minoxidil, finasteride, and RU58841. Users discuss the slow development of new treatments and the potential of hair transplants.

A woman experiencing hair loss and facial hair growth suspects PCOS or androgenic alopecia and is considering treatments like Rogaine, but is concerned about the cost. She has tried various hair care methods and is awaiting a hormone doctor appointment, while others suggest she may have a hormonal imbalance and recommend seeing a gynecologist or trying cheaper versions of Rogaine.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

User is experiencing hair loss despite using Minoxidil, finasteride, RU58841, dermarolling, and supplements like fish oil, collagen, hyaluronic acid, and biotin for over a year. They feel mentally distressed as their hair isn't growing longer and they avoid barbers and hats to hide thinning.

Beta blockers may cause hair thinning as a side effect. The user is concerned about this and seeks others' experiences with hair loss while using beta blockers.

A user is experiencing genetic hair loss and is using spironolactone and minoxidil without success. They are considering switching to vegan protein powder due to digestive issues and are concerned if it will worsen hair loss.

A 28-year-old male is experiencing hair loss, possibly due to seborrheic dermatitis, itchiness, or shampoo use, and is considering treatments other than minoxidil or finasteride. He plans to consult a doctor for further advice.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

A trans woman is curious about the impact of HRT on hair regrowth and scalp tension. Her current regimen includes finasteride, spironolactone, estradiol, ketoconazole, vitamin D, iron, and plans to add oral minoxidil and restart derma rolling.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user is experiencing increased hair thinning and shedding despite using oral dutasteride, oral minoxidil, topical dutasteride, and ketoconazole shampoo. Many recommend considering a hair transplant or embracing baldness, as current treatments seem ineffective.

Ashwagandha may cause hair thinning due to increased TSH levels, suggesting a link to hypothyroidism. Users are advised to consult a doctor for proper evaluation.

A user with seborrheic dermatitis is experiencing bald spots and hair thinning despite changing their diet and taking oral minoxidil. Another user suggests using ketoconazole shampoo properly, using a scalp massager, applying rosemary/peppermint oil, keeping hair short, and taking fish oil to improve scalp health.